Grant Details
Grant Number: |
3U01CA093332-05S1 Interpret this number |
Primary Investigator: |
Weeks, Jane |
Organization: |
Dana-Farber Cancer Inst |
Project Title: |
Lung/Colon Cancer Outcomes-Cancer Research Network |
Fiscal Year: |
2006 |
Abstract
DESCRIPTION (provided by applicant):
We will accrue all patients with newly diagnosed lung or colon cancer
receiving their care in one of five geographically diverse sites in the Cancer
Research Network, an NCI-funded research consortium of HMOs. Automated data
for all patients (2,058 patients with lung cancer over the two year enrollment
period, and 1,732 patients with colon cancer over the two year enrollment
period) will be supplemented with data obtained from complete medical record
review and patient surveys for a sample of 1,424 patients with newly diagnosed
lung cancer and 1,222 patients with newly diagnosed colon cancer. We will
oversample African-Americans, Asians and Pacific Islanders, as well as
Medicaid recipients. In addition, we will assemble an inception cohort of
patients with newly diagnosed metastatic recurrences of colorectal cancer
during the two-year enrollment period (projected at approximately 300
patients) for comprehensive data collection. We propose to lead analyses of
CanCORS-wide core data in order to (1) examine the effect of race and
ethnicity on patterns of care, treatment choice, quality of life, symptom
control, and satisfaction; (2) characterize the types of providers seen by
patients and examine the associations between provider
characteristics/attitudes and patterns of care and outcomes; (3) evaluate the
relationship between the structure/function of cancer care in the health care
delivery systems of participating patients and patient outcomes, including
health status, patient satisfaction, and cost; and (4) generate estimates of
utility weights and time- and out-of-pocket costs that are disease- and
treatment-specific for use in future cost-effectiveness analyses. Finally, in
a Special Research Study we will aggregate cost data for CRN CanCORS subjects
in order to (1) determine cancer-attributable phase-specific and lifetime
costs of care for colorectal and lung cancer; (2) determine the proportion of
total cancer-attributable costs that are spent on initial therapy versus
second- and third line therapies for each cancer, stratified by stage at
diagnosis; and (3) determine the relationship between type of initial therapy
and the subsequent lifetime cancer-attributable costs of care.
Publications
None. See parent grant details.